Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials

著者: Hung‐Yang Kuo, Kabir A. Khan, Robert S. Kerbel - Nature Reviews Clinical Oncology 2024 被引用: 98